Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings

ConclusionsNo new safety concerns were observed in this PMS study. Our results provide useful information regarding the status of crizotinib therapy in the clinical setting.

Source: Japanese Journal of Clinical Oncology - April 22, 2019 Category: Cancer & Oncology Source Type: research